Clinical possibilities of HER2-positive breast cancer diagnosis using alternative scaffold proteins-Reference-Cited by-同舟云学术

Clinical possibilities of HER2-positive breast cancer diagnosis using alternative scaffold proteins

Published:2022-10-15 Issue:3 Volume:21 Page:132-139
ISSN:1819-3684
Container-title:Bulletin of Siberian Medicine
language:
Short-container-title:Bûll. sib. med.

Author:

Bragina O. D.¹^ORCID,Chernov V. I.¹^ORCID,Deyev S. M.²^ORCID,Tolmachev V. M.³^ORCID

Affiliation:

1. Cancer Research Institute, Tomsk National Research Medical Center (NRMC), Russian Academy of Sciences; National Research Tomsk Polytechnic University

2. National Research Tomsk Polytechnic University; Shemyakin – Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences

3. National Research Tomsk Polytechnic University; Uppsala University

Abstract

HER2-positive breast cancer occurs in 15–20% of breast cancer patients and is associated primarily with a poor prognosis of the disease and the need for highly specific targeted therapy. Despite the clinical importance of determining HER2/neu, traditional diagnostic methods have their disadvantages and require the study of new additional research techniques.The information presented in this review makes it possible to consider current trends in the radionuclide diagnosis of HER2-positive breast cancer using the latest class of alternative scaffold proteins and to consider various aspects of their use in clinical practice.

Publisher

Siberian State Medical University

Subject

Molecular Medicine

Reference28 articles.

1. Han L., Li L., Wang N., Xiong Y., Li Y., Gu Y. Relationship of epidermal growth factor receptor expression with clinical symptoms and metastasis of invasive breast cancer. Interferon Cytokine Res. 2018;38(12):578–582. DOI: 10.1089/jir.2018.0085.

2. Zavyalova M., Vtorushin S., Krakhmal N., Savelieva O., Tashireva L., Kaigorodova E. et al. Clinicopathological features of non-specific invasive breast cancer according to its molecular subtypes. Experimental Oncology. 2016;38(2):122–127.

3. Pernas S., Tolaney S.M. HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance. Ther. Adv. Med. Oncol. 2019;11:1758835919833519. DOI: 10.1177/1758835919833519.

4. Babyshkina N., Malinovskaya E., Cherdyntseva N., Patalyak S., Bragina O., Tarabanovskaya N. et al. Neoadjuvant chemotherapy for different molecular breast cancer subtypes: a retrospective study in Russian population. Medical Oncology. 2014;31(9):1–12. DOI: 10.1007/s12032-014-0165-7.

5. Wolff A.C., Hammond M.E.H., Allison K.H., Harvey B.E., Mangu P.B., Bartlett J.M. et al. Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/ College of American pathologist clinical practice guideline focused update. Pathol. Lab. Med. 2018;142(11):1364–1382. DOI: 10.5858/arpa.2018-0902-SA.